Like other drugs in the [[fluoroquinolone]] class, delafloxacin contains a [[black box warning]] about the risk of  tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis. The label also warns against the risk of [[hypersensitivity reaction]]s and ''[[Clostridium difficile (bacteria)|Clostridium difficile]]''-associated diarrhea.<ref name=USlabel2017/>

 


 
Adverse effects occurring in more than 2% of clinical trial subjects included nausea, diarrhea, headache, [[elevated transaminases]], and vomiting.<ref name=USlabel2017/>

 

